Futura Medical Actions Higher After Emergency Treatment Update
By Michael Susin
Shares of Futura Medical PLC rose on Monday after it said it remained on track to submit its erectile dysfunction treatment MED3000 to the U.S. drug regulator by the end of the third quarter of 2022.
Shares at 09:00 GMT were up 3.30 pence, or 10%, to 34.90 pence.
The British pharmaceutical developer focused on sexual health and pain relief said it is conducting additional studies for the United States Food and Drug Administration as well as a short study on the ability of individuals to self-diagnose their erectile dysfunction and to select the treatment correctly.
The company said it is aiming for FDA clearance to sell MED3000 without a doctor’s prescription in the first quarter of 2023, becoming the first over-the-counter ED treatment.
âWe continue to make good progress in the regulatory process for MED3000 in the United States. expertise, âsaid CEO James Barder.
Write to Michael Susin at [email protected]